Endothelial JAK2V617F mutation leads to thrombosis, vasculopathy, and cardiomyopathy in a murine model of myeloproliferative neoplasm.

Melissa CastiglioneYa-Ping JiangChristopher MazzeoSandy LeeJuei-Suei ChenKenneth KaushanskyWei YinRichard Z LinHaoyi ZhengHuichun Zhan

Published in: Journal of thrombosis and haemostasis : JTH (2020)

These findings suggest that the JAK2V617F mutation can alter vascular endothelial function to promote cardiovascular complications in MPNs. Therefore, targeting the MPN vasculature represents a promising new therapeutic strategy for patients with MPNs.

Keyphrases

pulmonary embolism
heart failure
endothelial cells
cancer therapy
low grade
risk factors
drug delivery